What’s the deal with Alzheimer’s disease and amyloid?

Decades of Alzheimer's research focused on amyloid plaques may have been a costly diversion from more promising avenues. | Contesto: cronaca

Punti chiave

• What’s the deal with Alzheimer’s disease and amyloid?

Contesto

A foundational theory that has guided billions of dollars in Alzheimer's disease research for over thirty years is now facing a profound and unsettling reckoning. The long-held hypothesis, which posited that the accumulation of sticky amyloid-beta plaques in the brain was the primary cause of the devastating neurological disorder, appears to be a scientific blind alley. This conclusion emerges not from a single failed drug trial but from a persistent pattern of experimental therapies that successfully clear these plaques yet consistently fail to halt or meaningfully reverse cognitive decline in patients. The implications are seismic, suggesting that a generation of scientific effort and investment may have been directed at a symptom or a secondary effect, rather than the disease's root cause. The amyloid cascade hypothesis, first proposed in the early 1990s, offered a seemingly clear and compelling narrative. It suggested that the abnormal buildup of amyloid protein fragments triggered a toxic cascade, leading to the formation of tau protein tangles, widespread inflammation, brain cell death, and, ultimately, dementia. This theory became the central organizing principle for Alzheimer's research, shaping grant funding, drug development pipelines, and diagnostic criteria. Pharmaceutical companies raced to develop antibodies and other compounds designed to attack and clear amyloid plaques, with the expectation that doing so would alter the course of the disease. For years, the field operated on the assumption that it was only a matter of time and technical refinement before an effective anti-amyloid therapy would emerge. That confidence has been systematically eroded by a string of high-profile clinical failures. Drug after drug, including bapineuzumab, solanezumab, and gantenerumab, demonstrated an ability to reduce amyloid levels in the brain but showed no statistically significant benefit for patients' memory or daily function. The recent conditional approvals of newer antibodies like lecanemab and aducanumab, which show modest slowing of decline in specific early-stage populations, have done little to resolve the core dilemma. The clinical effects remain...

Lettura DEO

Decisione di validazione: publish

Risk score: 0.1

Il testo è stato ricostruito dai dati editoriali disponibili senza aggiungere fatti non presenti nel record sorgente.

Indicatore di affidabilità

Verificata — Alta confidenza. Fonti affidabili confermano la notizia.

Il sistema a semaforo

Ogni articolo su DEO include un indicatore di affidabilità:

• 🟢 Verificata — Alta confidenza. Fonti affidabili confermano la notizia.
• 🟡 In evoluzione — Confidenza moderata. Alcuni dettagli potrebbero ancora cambiare.
• 🔴 Contestata — Bassa confidenza. Fonti in conflitto o incertezze rilevanti.

Questo sistema esiste perché chi legge merita di sapere non solo cosa è successo, ma anche quanto la notizia è solida.

Categoria: cronaca